Here’s a finding that’s likely to divide opinion. A major new review published in The BMJ has found that despite producing substantial weight loss, most obesity medications - including popular GLP-1 drugs like Wegovy and Mounjaro - do not meaningfully improve quality of life or cardiovascular health.
That’s a headline that needs unpacking, because the reality is more nuanced than the takeaway suggests.
What the Review Actually Did
This wasn’t a single study - it was a network meta-analysis, which is one of the most powerful tools in evidence-based medicine. The researchers systematically reviewed and statistically combined results from multiple randomised controlled trials comparing different obesity drugs against each other and against placebo.
The review looked at a broad range of outcomes beyond just weight loss: quality of life measures, cardiovascular events, serious adverse events, and various metabolic markers. This is important because the obesity drug conversation has been overwhelmingly focused on one number - how many kilograms or pounds someone loses. This review asked a different question: does losing that weight actually make people feel better and live longer?
What the Research Says
The findings paint a complicated picture:
- Weight loss: Several GLP-1 receptor agonists produced significant weight loss compared to placebo. This part isn’t surprising - these drugs are well-established weight loss agents.
- Quality of life: Despite the weight loss, most of these medications did not produce meaningful improvements in quality of life scores. This is the finding that’s generating the most discussion.
- Cardiovascular health: Similarly, most drugs in the analysis did not show clear improvements in cardiovascular outcomes, though some individual trials (like SELECT for semaglutide) have shown cardiovascular benefits.
Expert reactions published alongside the review noted that while the drugs clearly work for weight loss, the disconnect between weight loss and quality of life improvement raises important questions about what we’re actually measuring and what we’re optimising for.
The Nuance That Matters
Now, before anyone takes this as evidence that “GLP-1 drugs don’t work,” let’s be clear about what this review is and isn’t saying.
Quality of life is notoriously hard to measure. The tools used to assess quality of life in clinical trials - standardised questionnaires like the IWQOL-Lite or EQ-5D - are blunt instruments. They might not capture improvements in mobility, self-confidence, sleep quality, joint pain, or the ability to play with your kids. These are things that matter enormously to individuals but are difficult to quantify in a randomised controlled trial.
Trial populations are not the real world. Clinical trial participants are selected under strict criteria and followed for defined periods. Quality of life improvements from weight loss might take longer to manifest than a 68-week trial can capture, or might be more pronounced in populations with different baseline characteristics.
The “so what” of weight loss. This review is really asking: is weight loss an end in itself, or a means to an end? If someone loses 15% of their body weight but doesn’t feel better, live longer, or have fewer heart attacks, what was the point? That’s a fair question - but it’s also possible the outcome measures just aren’t capturing the right things.
Some drugs did better than others. The meta-analysis found heterogeneity between different GLP-1 drugs. Not all of them performed identically. This is actually valuable information - it suggests the choice of compound matters, not just the class.
A Useful Counter-Narrative
What makes this review worth paying attention to is that it provides a counterweight to the dominant narrative around GLP-1 drugs. The conversation in mainstream media and even in some medical circles has been overwhelmingly celebratory: these drugs cause weight loss, weight loss is good, therefore these drugs are a breakthrough.
That narrative isn’t wrong, but it’s incomplete. If the goal of treating obesity is to improve people’s lives - not just to change a number on a scale - then we need to actually measure whether people’s lives are improving. This review says the evidence for that is weaker than you might expect.
For the research community, this kind of rigorous, large-scale analysis is exactly what’s needed. It doesn’t mean GLP-1 drugs are useless. It means we need to be more honest about what the evidence actually shows and what questions remain open.
The Australian Context
For Australians following the obesity medication landscape, this review is relevant because it directly affects how we think about access and availability. If the primary benefit of these medications is weight loss without clear quality of life or cardiovascular improvements, that changes the cost-benefit calculation for healthcare systems deciding whether to subsidise them.
The TGA has approved several GLP-1 medications for weight management in Australia, but access through the PBS remains limited. Reviews like this one are exactly the kind of evidence that regulators consider when making coverage decisions.
What Comes Next
The researchers and the accompanying expert commentary both call for better measurement tools and longer-term studies. That’s the right direction. We need:
- Quality of life instruments that capture the lived experience of weight loss more sensitively
- Longer follow-up periods that can detect cardiovascular benefits that may take years to emerge
- More granular analysis of which specific populations benefit most from which specific compounds
- Head-to-head trials that compare different GLP-1 drugs against each other, not just against placebo
In the meantime, if you’re interested in how different GLP-1 and multi-agonist compounds compare in ongoing research, have a look at our breakdown of retatrutide’s triple-agonist mechanism and our survodutide research overview.
Want to dig into the details? Join the conversation in the Grey Highway Telegram group where we discuss the latest research as it drops.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.